Metacartin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metacartin

Quick Facts

Classification Active Ingredient Therapeutic Use (General)
Nutraceutical Product / Carnitine Analog Levocarnitine (L-Carnitine) Treating carnitine deficiency, often in patients with end-stage renal disease (ESRD)

Metacartin is a brand name for the pharmaceutical compound Levocarnitine, which is also known as L-Carnitine. Levocarnitine is a naturally occurring quaternary ammonium compound that plays an essential role in mammalian energy metabolism. Specifically, it acts as a carrier molecule responsible for the transport of long-chain fatty acids into the mitochondria of cells, where they are oxidized to produce energy.

Primary Medical Use

Levocarnitine is a prescription medication primarily indicated for the prevention and treatment of carnitine deficiency. This deficiency can result from a genetic impairment of the body's ability to synthesize or utilize carnitine, or it can be a secondary condition resulting from inborn errors of metabolism. In clinical practice, parenteral (intravenous) Levocarnitine is also indicated for preventing and treating carnitine deficiency in patients with end-stage renal disease (ESRD) who are undergoing hemodialysis.

It is important to note that only the L-isomer of carnitine (Levocarnitine) is used by the body for these functions. The D,L-carnitine form is not used therapeutically for deficiency and can potentially interfere with the body's natural Levocarnitine processes.

What side effects are possible with Metacartin?

Possible side effects and safety information

Official regulatory documents classify the possible adverse effects of Levocarnitine (Metacartin) by frequency and the body system affected. These classifications are used by government health authorities to communicate the medicine's safety profile without interpretation or clinical advice.

Adverse Reaction Scope

The most commonly classified adverse reactions are generally confined to the gastrointestinal system and are designated as Common in official labeling. These include nausea, vomiting, diarrhea, and abdominal cramps. A transient, dose-related unpleasant body odor is also listed as a common effect.

Adverse effects falling under Nervous System Disorders and Cardiac Disorders are also documented. While their frequency often remains Not Known (not estimable from available data), regulatory bodies specifically note the occurrence of seizures (convulsions), which is considered a serious adverse reaction. Other reported effects include headaches, tachycardia, and hypertension.

Population-Specific Safety Considerations

The official safety information highlights specific considerations for certain patient groups:

  • Patients with Renal Impairment (Uremic Patients): The documentation notes a risk of developing or worsening myasthenia (muscle weakness), especially during long-term exposure. Worsening muscle weakness in this context is grouped under Musculoskeletal and Connective Tissue Disorders.
  • Patients with Seizure History: Individuals with a history of seizure activity should be monitored, as the medication may increase the frequency or severity of pre-existing seizure disorders.

Safety-Related Restrictions

Should the common adverse effect of body odor become persistent or distressing, official labeling states that a dose reduction or discontinuation of the medication may be necessary. This limitation ensures that the medicine's use is managed within defined, regulatory-acceptable safety boundaries.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Metacartin (Levocarnitine) provides specific guidance on overdosage, emphasizing a low acute toxicity profile. Prescribing information explicitly states that there have been no reports of toxicity resulting from levocarnitine overdosage. However, the ingestion of large doses may lead to one documented clinical manifestation: diarrhea. This physiological effect is the primary symptom associated with excessive exposure according to regulatory records.

Required Emergency Actions

In the event of a suspected overdosage, individuals must seek immediate medical attention for professional management. This action is required because the management of overdosage is constrained to supportive care administered by a medical professional. No specific antidote is known or documented in the official labeling.

Supportive Management

The regulatory guidance emphasizes that treatment must be supportive and symptomatic. The official labeling notes that levocarnitine is easily removed from plasma by dialysis. This procedural step is a key consideration in the management of overdosage, particularly for patients with End-Stage Renal Disease who may be receiving dialysis treatment. The overall regulatory structure mandates medical assistance to ensure proper symptomatic and procedural support.

Therapeutic Uses of Metacartin

What Metacartin Treats: Main Uses and Benefits

Metacartin (levocarnitine) is commonly used to help with the prevention and treatment of a medically diagnosed systemic carnitine deficiency. This supportive treatment is commonly used to help with managing the physical symptoms that interfere with daily functioning. It is considered relevant for situations involving severe metabolic manifestations like hypoketotic hypoglycemia and contributes to easing the overall symptom load related to pronounced fatigue and pervasive muscle weakness. This applies across domains where additional symptomatic support is needed, relevant in conditions presenting with systemic or localized discomfort linked to a carnitine deficit.

The medication is considered relevant in conditions characterized by periods of heightened symptoms that impact cardiovascular function (cardiomyopathy) and skeletal muscle strength—including inherited forms and deficiency linked to End-Stage Renal Disease (ESRD). Its use provides supportive relief that may help ease uncomfortable and recurrent physical manifestations, such as muscle cramps and symptoms of systemic imbalance during treatment. This support helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Support for Key Symptom Domains Levocarnitine is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability and supports patients during difficult episodes by easing distress.

Regulatory References

  1. NIH DailyMed service

Eligibility and Restrictions for Use

Who can and cannot use Metacartin? — Official Regulatory Information

The eligibility profile for Metacartin (Levocarnitine) is defined by a primary exclusion and specific conditional use rules documented in regulatory labeling.

Contraindicated Populations Absolute Exclusion
Hypersensitivity Patients with known allergy to levocarnitine or any of the formulation's components are absolutely prohibited from using the medicine.
Conditional Use & Restrictions Required Caution/Limitations
Severe Renal Impairment / ESRD Chronic administration of high doses of the oral form is not recommended due to the accumulation of potentially toxic metabolites (TMA and TMAO). The intravenous form is indicated for carnitine deficiency in patients with end-stage renal disease (ESRD) on hemodialysis.
Pregnancy Use is advised only if clearly needed, as adequate, well-controlled studies in pregnant women are not available.
Lactation/Nursing Mothers Use is conditional; the potential risks to the child from excess carnitine exposure must be weighed against the benefit to the mother. Discontinuation of nursing or treatment may be considered.
History of Seizures Patients must use with caution, as an increase in seizure frequency or severity has been reported.
Age Groups Use is established in pediatric and adult populations. Limited data on older adults suggests caution, but no specific differences in side effects or problems are expected compared to younger adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metacartin (levocarnitine) has documented interactions primarily with certain anticoagulant medicines and thyroid hormone analogues, which are classified as moderate-level clinical significance in regulatory documents.

Interacting Medicines and Required Constraints

Medicine Category Specific Interacting Agents Official Regulatory Constraint
Oral Anticoagulants Warfarin, Acenocoumarol Close monitoring of INR (blood clotting level); dose adjustment of the anticoagulant may be necessary.
Thyroid Hormone Analogues Thyroid hormone (e.g., Levothyroxine) Dose adjustment of the thyroid hormone may be necessary.

Interaction Details

Co-administration with oral anticoagulants such as Warfarin has been associated with an increased International Normalized Ratio (INR), which reflects a potentiation of the blood-thinning effect. This interaction carries an increased risk of bleeding. The official regulatory instruction is that patients on anticoagulant therapy must have their INR levels monitored appropriately and frequently, with the dosage of the anticoagulant potentially requiring revision after Metacartin treatment is initiated or adjusted.

Co-administration with thyroid hormone may result in a decrease in the hormone’s effectiveness. Therefore, patients may require monitoring and an adjustment of the thyroid hormone dosage to maintain therapeutic efficacy. The official documents require that these combinations be used with caution and close supervision.

Mechanism of Action

How Metacartin works

Metacartin, as Levocarnitine, functions as an essential carrier molecule within the Carnitine Shuttle System. Its primary mechanism involves acting as a substrate and cofactor for the Carnitine Palmitoyltransferase I (CPT I) and II (CPT II) enzymes and the Carnitine-Acylcarnitine Translocase (CACT). This interaction directly enables the movement of long-chain fatty acids across the mitochondrial membrane, supporting the key pathway of fatty acid beta-oxidation and facilitating ATP (cellular energy) production in high-demand tissues.

In a secondary, yet vital action, Levocarnitine facilitates the clearance of metabolic byproducts. It acts as a buffer by binding to short- and medium-chain acyl-CoA esters, converting them into forms that can be exported from the mitochondria. This process ensures the constant availability of free Coenzyme A (CoA), thereby mitigating the inhibition of other critical enzymes and maintaining the overall efficiency of cellular metabolic pathways.

The drug's activity is highly specific, limited to the biologically active L-stereoisomer, and is constrained by carrier-dependent kinetics relying on dedicated transporters. The mechanism is vulnerable to competitive inhibition by non-functional structural analogs, which can block specific transport sites.

Dosage and Administration Information

Metacartin (levocarnitine) administration follows distinct routes and dosing regimens for different clinical needs. The medication is primarily administered via the oral route for long-term maintenance of systemic deficiency or intravenously (IV) for acute metabolic events and for treating deficiency associated with end-stage renal disease (ESRD). The usage protocol is structured around the patient’s clinical status and tolerance.

Oral dosing for adults typically starts at 1 gram daily and is titrated upward to a usual maximum of 3 grams per day, administered in two or three evenly divided doses. To enhance physical tolerance and absorption, the oral forms, including the solution, are preferably taken during or following meals. The oral solution should be consumed slowly or may be dissolved in liquid food.

For patients with ESRD undergoing hemodialysis, the IV formulation is administered at a dose of 10 to 20 mg/kg of dry body weight, given into the venous return line after each dialysis session. Acute metabolic crises require IV administration of 50 mg/kg as a slow injection or infusion, repeated every three to six hours during the first 24 hours. Dosage titration is a key procedural component, requiring a slow and gradual increase from the starting regimen, guided by the patient's response. Chronic high-dose oral administration is generally constrained in individuals with severely compromised renal function due to the potential for metabolite accumulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metacartin (Levocarnitine)

Research Evidence for Systemic Carnitine Deficiency

Research explored the use of Metacartin for systemic carnitine deficiency, including inherited metabolic conditions. Due to the critical nature of the condition, the evidence primarily consists of observational studies and case series, as large, placebo-controlled trials are not typically conducted. Studies monitored biochemical measures, such as plasma carnitine levels and acyl-CoA compounds. Findings reported measurements showing an increase in carnitine levels in observed populations. Research also described monitoring of clinical manifestations like cardiac function and acute metabolic episodes. The evidence level is considered High for the findings related to biochemical markers, but long-term outcomes are not well characterized by controlled trials.

Research Evidence for Kidney Disease and Hemodialysis

For carnitine deficiency secondary to End-Stage Renal Disease (ESRD) in patients undergoing hemodialysis, the research base includes Randomized Controlled Trials (RCTs) compared to placebo. These studies monitored adult and pediatric patients, primarily examining physical discomfort and systemic imbalance. All studies consistently reported measurements of an increase in plasma carnitine concentration, which was a primary endpoint. However, research exploring clinical outcomes such as exercise tolerance, muscle cramps, and hypotension documented mixed or inconsistent findings when compared to placebo.

Evidence Quality and Duration

The follow-up duration differs across the evidence base. While long-term observational data tracks patients with inherited deficiencies over many years, the RCTs involving the kidney disease population focused on short- to intermediate-term follow-up, typically 12 to 24 weeks. Overall, certainty remains low when evaluating the data related to several key symptomatic clinical outcomes, as consistent patterns related to improvement have not been established across the existing controlled research. Furthermore, data for certain special populations, such as pregnant individuals, remain insufficient.

Key Studies & References

  1. Label: CARNITOR (Levocarnitine) Injection, Solution (Covers both IEM and ESRD indications)
  2. Primary Carnitine Deficiency - GeneReviews® - NCBI Bookshelf (Guideline on management, long-term observation)

Frequently Asked Questions (FAQ)

Common questions about Metacartin (FAQ)

Q: How does Metacartin help with energy levels?

A: Metacartin's active ingredient, Levocarnitine, plays a key role in the body’s energy metabolism. According to official product information, it acts as a carrier molecule that helps transport long-chain fatty acids into the mitochondria of cells. Once inside, these fatty acids are broken down to produce energy (ATP), which supports the body's energy-intensive processes.

Q: Can Metacartin cause changes in appetite?

A: Regulatory documents list a loss of appetite as a less common side effect that may occur in some patients taking Levocarnitine. If significant or concerning changes in appetite or overall health are observed, these observations are important to share with the prescribing physician.

Q: Can Metacartin be crushed or mixed with food?

A: Official information for the oral solution form states it may be consumed alone or dissolved in liquid foods or beverages. Regulatory information for the tablet formulation typically advises swallowing it whole and avoiding crushing or chewing. Specific product instructions should always be consulted for administration details.

Q: Does Metacartin come in different forms (e.g., tablet, liquid, injection)?

A: Yes, Metacartin (Levocarnitine) is available in several formulations for use under different administration protocols. These typically include oral tablets, an oral solution (which may be sugar-free), and a solution for intravenous injection, which is generally administered in a clinical setting.

Q: Are there any known interactions between Metacartin and herbal supplements?

A: While specific interactions with herbal supplements are not always listed, official drug labeling stresses the importance of disclosing all medicines, vitamins, and herbal products to a healthcare professional. This helps ensure that potential interaction risks are properly managed.

Q: How quickly should I expect to feel the effects of Metacartin?

A: Pharmacokinetic data shows that Levocarnitine reaches its maximum concentration in the blood within a few hours after an oral dose. Clinical effects related to the body's carnitine levels are typically assessed by health professionals over several weeks or months of continuous treatment.

Q: Is Metacartin safe to take long-term?

A: Official labeling suggests caution regarding long-term use of high oral doses for individuals with severe kidney problems. This restriction is related to the potential accumulation of certain metabolites (TMA/TMAO) in the body.

Q: Is it normal to feel a bit restless after starting Metacartin?

A: Official safety information notes that Levocarnitine has been associated with effects on the nervous system, including headaches and, in rare instances, seizures. If unusual feelings such as restlessness, anxiety, or uncontrolled movements occur, such feelings should be discussed with the prescribing physician.

Q: Is Metacartin considered a standard treatment in Europe/US?

A: Yes, the active ingredient Levocarnitine is an authorized prescription medicine for its specific indications related to carnitine deficiency. It is an FDA-approved drug in the United States and holds marketing authorization from the European Medicines Agency (EMA).

Q: How long does Metacartin stay in your system?

A: Pharmacokinetic studies indicate that following a single intravenous dose, the medicine's elimination half-life is approximately 17.4 hours. The way the body processes and eliminates the medicine differs between oral and intravenous administration.

Q: Are there any studies on Metacartin's use in healthy people?

A: Regulatory documents detailing how the drug is handled by the body (pharmacokinetics) may include data gathered from studies conducted in healthy volunteers. These studies help establish how the medicine is absorbed, distributed, and eliminated.

Q: Are there any restrictions on driving or operating machinery while taking Metacartin?

A: Safety documents indicate that the ability to drive or operate machinery may be affected if the medicine causes side effects such as seizures or dizziness. If these effects occur, caution is warranted.

Q: Is Metacartin a drug that requires blood monitoring?

A: Yes, close monitoring of blood parameters may be required for certain patients. Specifically, if Metacartin is taken alongside certain blood-thinning medicines (anticoagulants), regulatory documents mandate frequent testing of blood clotting levels (INR). Follow-up lab tests are also generally advised during treatment.

Q: Does Metacartin have a bitter or unpleasant taste (if liquid form)?

A: The oral solution is formulated to be taken directly or dissolved in liquids or liquid foods. Taking the solution this way is often suggested in official labeling to aid tolerance and absorption.

Q: Are there any long-term side effects to worry about with Metacartin?

A: Official safety information notes that in people with severe kidney impairment, long-term use is associated with a reported risk of developing or worsening muscle weakness (myasthenia). Healthcare professionals may monitor for these issues, especially in individuals with a history of seizures or severe kidney conditions.

Q: Can Metacartin be taken on an empty stomach?

A: Official instructions advise taking the oral forms of Metacartin, whether tablets or solution, preferably during or following meals. This timing is recommended to support better absorption and help minimize potential digestive side effects.

Q: Does Metacartin have a generic version available?

A: Yes, the active ingredient Levocarnitine is available in generic versions approved by the FDA. This includes generics for the oral solution, tablet, and injectable formulations.

Q: When is the best time of day to take Metacartin?

A: Official regulatory guidance advises spacing doses appropriately throughout the day to support absorption. To help with absorption and tolerance, it is typically recommended to take the doses during or after meals.

Q: Does alcohol interact negatively with Metacartin?

A: The official product labeling for Metacartin does not typically list alcohol as a specific named interaction. However, health authorities often note that a person’s use of alcohol while taking any prescription medication should be addressed by their healthcare professional.

Q: Can Metacartin cause skin rash or itching?

A: Official safety documents mention that serious hypersensitivity reactions have been reported in connection with Levocarnitine use. Signs of an allergic reaction can include skin reactions such as rash, itching (urticaria), and swelling.

How should Metacartin be stored and disposed of?

How to Store and Dispose of Metacartin?

The official storage and disposal instructions for Metacartin (Levocarnitine oral solution) ensure product stability and safety according to regulatory labeling.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature (25 C / 77 F), with excursions permitted up to 30 C (86 F).
Protection Protect from Freezing, light, and moisture. Store in the original container.
Child Safety Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired Metacartin must be disposed of according to local regulations for pharmaceutical waste. Consumers should follow the safe drug disposal guidelines provided by their national health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metacartin found in:

A-Z Index: